CFDA Solicits Comments on Drug Registration Rules

Published date02 August 2016
Law FirmRopes & Gray LLP
AuthorKatherine Wang
Subject MatterChina,China FDA,Clinical Trials,Comment Period,Pharmaceutical Industry,Research and Development

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT